Overview
Imeglimin is a first-in-class oral antihyperglycemic agent developed for the treatment of type 2 diabetes. It belongs to the glimins class of drugs, which work by targeting mitochondrial function to improve glucose metabolism. Imeglimin has shown promise in clinical trials for its efficacy and safety profile, making it a valuable addition to diabetes management therapies. Approved in Japan and under review in other regions, Imeglimin represents a significant advancement in diabetes care. Its unique mechanism of action differentiates it from other antidiabetic drugs, offering potential benefits for patients with varying degrees of insulin resistance.
Physical and Chemical Properties
Imeglimin is a white to off-white crystalline powder with a molecular weight of 159.19 g/mol. It is soluble in water, which facilitates its formulation into oral dosage forms. The compound has a melting point of approximately 150-155°C, indicating stability under normal storage conditions. Chemically, Imeglimin is characterized by its molecular formula C6H13N3O2. Its structure includes functional groups that contribute to its pharmacological activity, particularly its ability to modulate mitochondrial function and improve glucose uptake in cells.
Main Applications
Imeglimin is primarily used for the treatment of type 2 diabetes. It is often prescribed as part of a comprehensive diabetes management plan that includes diet, exercise, and other medications. The drug's ability to improve glucose metabolism makes it particularly useful for patients who have not achieved adequate glycemic control with other therapies. In addition to its primary use, ongoing research is exploring potential applications of Imeglimin in other metabolic disorders. Its mechanism of action suggests it may have benefits beyond glucose control, including protective effects on pancreatic beta cells.
Safety and Storage
Imeglimin should be stored in a cool, dry place away from direct sunlight to maintain its stability. Proper handling procedures, including the use of personal protective equipment, are recommended to minimize exposure during manufacturing and formulation processes. As with all pharmaceuticals, adherence to safety data sheet guidelines is essential. Imeglimin has a favorable safety profile in clinical trials, but healthcare providers should monitor patients for potential side effects, particularly during the initial phases of treatment.
B2B Procurement Guide
When procuring Imeglimin for pharmaceutical use, it is critical to source from suppliers who comply with Good Manufacturing Practices (GMP) and other regulatory standards. Buyers should verify the supplier's certification and quality control processes to ensure the product meets pharmaceutical-grade requirements. Price ranges for Imeglimin can vary based on quantity, supplier, and market conditions. Bulk purchases may offer cost advantages, but buyers should balance price considerations with quality assurance. Long-term supply agreements can help stabilize procurement costs and ensure consistent availability.
Related Manufacturers
- 主营：恶唑烷、赤霉素、溴苯基、依格列明盐酸、联噻吩、果糖嗪、咪唑并、屎米酮、碘吡啶、氟苯基、安美速、s-4-苄基、3-溴吲哚、4-氯吡啶、1-乙酸基、氯苯甲酸、咪唑乙醇、氧代丙腈、贝达喹啉、贝伐单抗、谷氨酰胺、喹啉-21氢、决明内酯、溴喹唑啉、苯基丙基、乙基己基